1
Exhibit 99 (b)
--------------------------------------------------------------------------------
MERCK & CO., INC.
FIRST QUARTER
1Q `01 1Q `00 % CHG.
--------------------------------------------------------------------------------
TOTAL SALES $ 11,345.1 $ 8,851.4 28%
----------- ----------
TOTAL COSTS, EXPENSES, & OTHER $ 8,977.6 $ 6,657.4
----------- ---------
Materials & Production 7,046.5 4,833.4
Marketing & Administrative 1,506.2 1,417.2
Research & Development 547.4 523.6
Equity Income From Affiliates (178.6) (188.3)
Other (Income)/Expense, Net 56.1 71.5
PRE-TAX INCOME $ 2,367.5 $ 2,194.0
TAXES $ 710.2 $ 694.4
TAX RATE 30.0% 31.6%
NET INCOME $ 1,657.3 $ 1,499.6 11%
EPS - ASSUMING DILUTION $0.71 $0.63 13%
AVG. # SHARES - ASSUMING DILUTION 2,345.9 2,363.1
--------------------------------------------------------------------------------
1Q `01 % CHG. VOL PX FX
------ ------- --- -- --
TOTAL SALES $11,345 28% 24 6 -2
------- --- -- -- --
Total U.S. and Foreign Sales 4,965 8% 10 1 -3
----- -- -- -- --
U.S. 3,155 8% 6 2 0
Foreign 1,810 7% 15 0 -8
Other Medco Sales 6,380 51%
--------------------------------------------------------------------------------
2
Exhibit 99 (b)
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FIRST QUARTER
2001
================================================================================
OTHER (INCOME)/EXPENSE, NET
---------------------------
1Q `01 1Q `00
-----------------------------------------------------------------------------
INTEREST INCOME $(136.1) $ (94.7)
INTEREST EXPENSE 110.7 117.3
EXCHANGE (GAINS)/LOSSES (12.6) (7.8)
MINORITY INTERESTS 85.2 60.2
AMORTIZATION OF GOODWILL AND INTANGIBLES 80.6 78.8
Other, net (71.7) (82.3)
---------------------------
TOTAL $ 56.1 $ 71.5
-----------------------------------------------------------------------------
================================================================================
JOINT VENTURE SALES DETAIL
All sales reported here are end-market JV sales, presented on a "NET" basis,
rounded to the nearest $5 million.
----------------------------
MERIAL 1Q `01 1Q `00
-------------------------------------------------------------------------------
IVOMEC, HEARTGARD, other avermectins $ 110 $ 105
FRONTLINE 115 65
Biologicals 80 80
Other Animal Health 45 50
Poultry Genetics 50 55
---------------------------
TOTAL MERIAL SALES $ 400 $ 355
-----------------------------------------------------------------------------
---------------------------
AVENTIS PASTEUR-MSD 1Q `01 1Q `00
--------------------------------------------------------------------------------
HEPATITIS VACCINES $ 25 $ 40
VIRAL VACCINES 15 15
Other Vaccines 65 65
---------------------------
TOTAL AP-MSD SALES $ 105 $ 120
-----------------------------------------------------------------------------
================================================================================
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
--------------------------------
2001 2000 % CHG
-----------------------------------------------------------------------------
FIRST QUARTER 138 99 39%
-----------------------------------------------------------------------------
3
Exhibit 99 (b)
MERCK & CO., INC.
PRODUCT SALES DETAIL
----------------------------------------------------------------------------------
1Q `01 vs. 1Q `00
----------------------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
-----------------------------
PRODUCT % CHG $ % CHG $ % CHG $
-----------------------------------------------------------------------------------------------------------------
VIOXX 31% $485 15% $350 N/M $135
-----------------------------------------------------------------------------------------------------------------
VASOTEC / VASERETIC -45% 260 -83% 35 -15% 225
-----------------------------------------------------------------------------------------------------------------
PRINIVIL / PRINZIDE 24% 365 28% 340 -17% 25
-----------------------------------------------------------------------------------------------------------------
COZAAR / HYZAAR 5% 385 -10% 140 17% 245
-----------------------------------------------------------------------------------------------------------------
MEVACOR 16% 145 25% 125 -20% 20
-----------------------------------------------------------------------------------------------------------------
ZOCOR 31% 1,515 48% 1,050 3% 465
-----------------------------------------------------------------------------------------------------------------
AGGRASTAT 0% 30 -40% 15 N/M 15
-----------------------------------------------------------------------------------------------------------------
SINGULAIR 76% 300 77% 230 75% 70
-----------------------------------------------------------------------------------------------------------------
MAXALT 38% 55 50% 45 0% 10
-----------------------------------------------------------------------------------------------------------------
PROPECIA 0% 50 50% 30 -33% 20
-----------------------------------------------------------------------------------------------------------------
PROSCAR 19% 125 33% 60 8% 65
-----------------------------------------------------------------------------------------------------------------
PRIMAXIN -3% 145 -11% 40 0% 105
-----------------------------------------------------------------------------------------------------------------
CANCIDAS N/M 5 N/M 5 N/M -
-----------------------------------------------------------------------------------------------------------------
PEPCID -10% 185 -8% 170 -25% 15
-----------------------------------------------------------------------------------------------------------------
FOSAMAX 27% 350 29% 245 24% 105
-----------------------------------------------------------------------------------------------------------------
CRIXIVAN/STOCRIN -11% 125 -20% 40 -6% 85
-----------------------------------------------------------------------------------------------------------------
TIMOPTIC/TIMOPTIC XE -8% 60 -25% 15 0% 45
-----------------------------------------------------------------------------------------------------------------
TRUSOPT/COSOPT 12% 95 38% 55 -11% 40
-----------------------------------------------------------------------------------------------------------------
HEPATITIS VACCINES 13% 90 14% 80 0% 10
-----------------------------------------------------------------------------------------------------------------
VIRAL VACCINES 9% 125 5% 110 N/M 15
-----------------------------------------------------------------------------------------------------------------
OTHER VACCINES 67% 25 N/M 25 N/M -
-----------------------------------------------------------------------------------------------------------------
NOTE: Product sales rounded to the nearest $5 million.
N / M - Not Meaningful
